GLOW Stack: GHK-Cu + Epitalon + NAD+ Longevity Protocol Research Guide

The GLOW stack pairs three compounds — GHK-Cu (copper tripeptide), Epitalon (Ala-Glu-Asp-Gly tetrapeptide), and NAD+ (nicotinamide adenine dinucleotide) — that operate through mechanistically orthogonal longevity pathways. Each targets a distinct hallmark of aging: GHK-Cu addresses extracellular matrix decline and oxidative stress, Epitalon targets telomere attrition and circadian disruption, and NAD+ restores the depleted coenzyme substrate that fuels sirtuin-mediated repair and mitochondrial biogenesis. This guide covers the rationale for combining all three, the published data supporting each compound, practical protocol design considerations, and endpoint selection for longevity-oriented research.

Why Three Compounds? The Orthogonal Pathway Rationale

Aging is multi-mechanistic. No single intervention addresses all nine hallmarks of aging described by Lopez-Otin et al. (2013, Cell). The GLOW stack is designed around the principle that combining compounds with non-competing primary targets — each addressing a different hallmark — may produce additive or synergistic effects without the receptor saturation or pathway competition risks that arise when stacking compounds targeting the same receptor (such as combining two GHSR-1a agonists).

The three GLOW compounds map to distinct hallmarks: GHK-Cu to loss of proteostasis and altered intercellular communication (ECM remodeling, Nrf2 antioxidant defense), Epitalon to telomere attrition and genomic instability (TERT activation, melatonin restoration), and NAD+ to mitochondrial dysfunction and epigenetic alterations (SIRT1/3/6 deacetylation, PGC-1alpha biogenesis). There is no receptor overlap, no competitive binding, and minimal pharmacokinetic interaction between the three compounds.

GHK-Cu: Extracellular Matrix and Nrf2 Antioxidant Defense

GHK-Cu (Gly-His-Lys copper complex, CAS 89030-95-5, MW 403.93 g/mol) is a naturally occurring human serum tripeptide that declines approximately 60% between ages 20 and 60. It functions as both a copper delivery system and a gene-regulatory peptide, with Pickart's comprehensive gene expression analysis demonstrating significant modulation of over 4,000 genes — including upregulation of collagen synthesis (TGF-beta1/COL1A1/COL3A1), downregulation of matrix metalloproteinases (MMP-1, MMP-2, MMP-9), and activation of the Nrf2/Keap1 antioxidant pathway (GCLC for glutathione synthesis, HO-1, NQO1).

In the context of the GLOW stack, GHK-Cu provides the structural repair component. Leyden et al. (2004) demonstrated measurable improvements in skin thickness, density, and firmness in human subjects using topical GHK-Cu. Preclinical wound healing studies consistently show accelerated re-epithelialization, increased CD31-positive vessel density, and enhanced collagen deposition. The Nrf2 antioxidant arm is particularly relevant for longevity: GHK-Cu upregulates glutamate-cysteine ligase catalytic subunit (GCLC), which is the rate-limiting enzyme for glutathione (GSH) synthesis — the master intracellular antioxidant.

GHK-Cu Dosing in Preclinical Models

Published systemic doses for GHK-Cu in rodent models range from 1-10 mg/kg SC or IP, typically administered daily or every other day. Topical applications use 0.1-2% w/w formulations. For the GLOW stack, systemic administration is preferred to achieve both dermal and systemic Nrf2 activation. The characteristic blue-violet color of the reconstituted solution provides a useful quality indicator — deviation from this color suggests copper loss or degradation.

Epitalon: Telomerase Activation and Pineal Restoration

Epitalon (also spelled Epithalon; Ala-Glu-Asp-Gly, CAS 307297-39-8, MW 390.35 g/mol) is a synthetic tetrapeptide analog of Epithalamin, a pineal gland extract studied extensively by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology. Epitalon activates telomerase reverse transcriptase (TERT) expression, the catalytic subunit responsible for telomere elongation.

Khavinson et al. (2003) demonstrated a 2.4-fold increase in telomerase activity using the TRAP (Telomeric Repeat Amplification Protocol) assay in human fetal fibroblast cultures treated with Epitalon. Telomere elongation of 200-500 base pairs was observed in lymphocyte cultures with TERT mRNA upregulation confirmed by RT-qPCR. In rodent lifespan studies, CBA and C57BL/6 mice receiving Epitalon (1 microgram/mouse SC, administered in pulsatile 10-day courses) showed 12-20% maximum lifespan extension with delayed thymic involution, preserved splenic architecture, and reduced spontaneous tumor incidence in C3H/He mammary tumor models.

Beyond telomerase, Epitalon restores melatonin synthesis in aged pineals by upregulating arylalkylamine N-acetyltransferase (AANAT), the rate-limiting enzyme in melatonin biosynthesis. This has downstream effects on circadian rhythm normalization and HPA axis cortisol patterns. Melatonin itself is a potent mitochondrial antioxidant, creating an indirect link between Epitalon and mitochondrial protection that complements the direct mitochondrial effects of NAD+.

Epitalon Protocol Design

Epitalon is typically administered in pulsatile courses rather than continuously — 10-day treatment courses with 10-20 day washout periods. This mirrors the published rodent protocols (Khavinson) and aligns with the biology: telomerase activation is a gene expression event, not a continuous receptor occupancy phenomenon. Published preclinical doses are 1 microgram/mouse SC (~40-50 mcg/kg) or 1-5 micrograms/rat SC. Importantly, Epitalon should be reconstituted in sterile saline rather than BAC water, as the 0.9% benzyl alcohol preservative may interfere with the small tetrapeptide's stability profile.

NAD+: Sirtuin Fuel and Mitochondrial Biogenesis

NAD+ (nicotinamide adenine dinucleotide, CAS 53-84-9, MW 663.43 g/mol) is the essential coenzyme for sirtuins (SIRT1-7), PARPs, and CD38 — the master repair and maintenance enzymes of the cell. NAD+ levels decline 40-60% in aged tissues (Rajman et al., 2018, Cell Metabolism), creating a metabolic crisis where repair enzymes compete for an insufficient substrate pool. SIRT1 deacetylation of PGC-1alpha drives mitochondrial biogenesis; SIRT3 deacetylation of SOD2 (K68/K122) and IDH2 generates NADPH for glutathione recycling; SIRT6 is required for base excision repair at double-strand breaks.

In the GLOW stack, NAD+ provides the metabolic fuel that supports the cellular repair processes initiated by GHK-Cu and Epitalon. Gomes et al. (2013, Cell) demonstrated that NMN (500 mg/kg/day IP) reversed age-related mitochondrial decline in aged muscle within one week — restoring Complex I activity, NAD+/NADH ratio, and exercise tolerance. Direct IP NAD+ achieves ~5-fold greater plasma elevation than equimolar oral NMN or NR (Pencina et al., 2023, Nature Aging), bypassing the NAMPT/NMRK/NMNAT enzymatic bottlenecks.

NAD+ Handling Requirements

NAD+ requires careful handling. The nicotinamide ring is light-sensitive (absorption at 259 nm), requiring amber vials for all storage. NAD+ should be reconstituted in sterile saline or PBS — never BAC water, as benzyl alcohol can promote oxidation of the nicotinamide ring. Prepare working solutions fresh when possible; freeze aliquots at -80 degrees C for multi-day protocols. Published preclinical doses for direct NAD+ are 250-500 mg/kg IP for acute studies.

Synergy Architecture: Why These Three Compounds Together

The GLOW stack was designed around three-layer synergy — each compound enhances the conditions for the others to work optimally:

• Layer 1 — Antioxidant Foundation: GHK-Cu activates Nrf2, upregulating glutathione synthesis (GCLC) and HO-1. This reduces the oxidative burden on mitochondria, creating a cleaner environment for NAD+-dependent sirtuin activity. NAD+/SIRT3 activates SOD2 (mitochondrial superoxide dismutase) through a separate, non-competing antioxidant axis. Together, they cover cytosolic (GSH via GHK-Cu) and mitochondrial (SOD2 via NAD+/SIRT3) ROS management.
• Layer 2 — Telomere-Mitochondria Crosstalk: Epitalon activates TERT, but telomerase function requires adequate cellular energy (ATP from functional mitochondria) and protection from oxidative telomere damage (8-oxo-dG lesions). NAD+/SIRT1-driven mitochondrial biogenesis ensures the energy supply, while the GHK-Cu/Nrf2 antioxidant arm reduces the oxidative burden on telomeric DNA. This creates a permissive environment for TERT to extend telomeres rather than merely being activated in an oxidatively stressed cell.
• Layer 3 — ECM Quality Requires Cellular Health: GHK-Cu upregulates collagen synthesis, but collagen is an energy-intensive process (4-hydroxyproline post-translational modification requires oxygen, Fe2+, and alpha-ketoglutarate — all tied to mitochondrial function). NAD+/PGC-1alpha-driven mitochondrial efficiency supports the biosynthetic demands of ECM remodeling initiated by GHK-Cu.

Protocol Design: Timing, Sequencing, and Cycle Structure

The three compounds in the GLOW stack have different pharmacokinetic profiles and optimal administration patterns, which must be coordinated in a research protocol:

A typical 12-week research protocol would structure Epitalon in three 10-day courses (weeks 1-2, weeks 5-6, weeks 9-10) while GHK-Cu and NAD+ run continuously. This pulsatile Epitalon schedule mirrors published longevity protocols and avoids potential continuous exposure issues. NAD+ can be administered daily or on a 5-on/2-off schedule to allow NAMPT/salvage pathway normalization on off days.

Endpoint Selection for Longevity Research

The GLOW stack targets multiple biological systems, requiring a multi-modal endpoint panel. The minimum recommended panel includes:

The 8-OHdG (8-hydroxydeoxyguanosine) marker is particularly informative as a convergence endpoint — it reflects oxidative DNA damage that all three compounds are expected to reduce through their respective mechanisms (Nrf2/GSH, melatonin/SOD, SIRT3/SOD2). Measuring it at multiple timepoints provides an integrated readout of total anti-oxidant efficacy.

Critical Controls for GLOW Stack Research

A rigorous GLOW stack study requires careful control design. The ideal minimum is a 5-group protocol:

• Group 1: Vehicle only (matched saline injections on all schedules)
• Group 2: GHK-Cu alone (to isolate ECM/Nrf2 effects)
• Group 3: Epitalon alone (to isolate telomerase/melatonin effects)
• Group 4: NAD+ alone (to isolate sirtuin/mitochondrial effects)
• Group 5: GLOW stack (all three combined)

This 5-group design allows determination of whether the combination produces additive or synergistic effects beyond individual compounds. A full factorial design (2x2x2 = 8 groups) provides even more rigorous interaction analysis but requires substantially more animals. At minimum, groups 1 and 5 are essential; groups 2-4 provide mechanism attribution.

Additional critical controls include: free GHK (without copper) + CuSO4 controls to confirm the copper complex is required, not just either component alone; NAMPT inhibitor FK866 rescue experiments to confirm NAD+ effects are sirtuin-dependent; and luzindole (melatonin receptor antagonist) to dissect Epitalon's direct TERT effects from its melatonin-mediated effects.

Common Protocol Mistakes to Avoid

• Using BAC water for NAD+ reconstitution — benzyl alcohol promotes nicotinamide ring oxidation. Use sterile saline or PBS exclusively.
• Using BAC water for Epitalon — the small tetrapeptide may show reduced stability in benzyl alcohol. Sterile saline is recommended.
• Storing GHK-Cu in EDTA-containing tubes — EDTA chelates the copper ion, destroying the complex. Use standard polypropylene or glass vials.
• Continuous Epitalon dosing instead of pulsatile — published protocols use 10-day courses. Continuous exposure does not match the gene-regulatory mechanism (TERT transcription induction, not receptor occupancy).
• Failing to use amber vials for NAD+ — photodegradation at 259 nm reduces potency. All NAD+ solutions must be protected from light.
• Mixing all three compounds in a single reconstitution vial — the pH, stability, and handling requirements differ. Reconstitute and store each compound separately.
• Forgetting to standardize circadian timing — melatonin sampling for Epitalon endpoints must be collected during the dark phase (ZT18 in standard 12:12 light cycle). NAD+ levels also oscillate with circadian rhythm.

Reconstitution Protocol Summary

Suggested 12-Week Protocol Timeline

The following timeline integrates the three compounds with their distinct administration schedules, optimized for a standard 12-week preclinical longevity study in aged (18-22 month) C57BL/6J mice:

Cost and Supply Planning

For a 12-week study with 10 mice per group (5 groups = 50 mice, C57BL/6J 25g average), approximate compound requirements: GHK-Cu at 1 mg/kg daily x 84 days x 50 mice = 105 mg total (approximately 2 vials at 100 mg each to allow for reconstitution losses). Epitalon at 1 mcg/mouse x 30 days (three 10-day courses) x 50 mice = 1.5 mg total (one 10 mg vial provides substantial surplus). NAD+ at 250 mg/kg x 0.025 kg x 84 days x 50 mice = 26,250 mg total (~26 vials at 100 mg each). NAD+ is the primary cost driver due to its high required dose relative to the other two compounds.

Research Design Considerations

• Age matters: Use genuinely aged animals (18-22 months for mice). Young animals have high baseline NAD+, long telomeres, and robust ECM — the GLOW stack addresses age-related declines, so young animals may show minimal effect, producing a misleading negative result.
• Sex stratification: Female mice show 1.5-2x higher baseline adiponectin and different Nrf2 response kinetics. Include both sexes per NIH SABV policy and power each sex independently.
• Circadian standardization: NAD+ and melatonin both oscillate with circadian rhythm. Standardize all dosing and sampling to specific Zeitgeber times (ZT). Dose NAD+ at ZT0-2 (early light phase). Sample melatonin at ZT18 (dark phase).
• Compound-specific negative controls: Include free GHK + CuSO4 control for GHK-Cu mechanism, FK866 (NAMPT inhibitor) control for NAD+, and luzindole (melatonin antagonist) control for Epitalon melatonin-dependent effects.
• Do not pool reconstituted compounds: Despite the convenience, the three compounds have different pH optima, storage requirements, and stability profiles. Reconstitute, store, and inject each separately.
• Telomere measurement timing: TRAP assay for telomerase activity should be performed within 24-48 hours post-Epitalon course completion (when TERT expression peaks). Telomere length measurement (qFISH/Southern) requires longer intervals (6-12 weeks) to detect meaningful elongation.

Comparison with Individual Compound Protocols

Researchers may ask whether the GLOW stack adds value over single-compound longevity protocols. The answer depends on the research question. For mechanism-focused studies dissecting a single pathway (e.g., TERT regulation), single-compound protocols are cleaner and more interpretable. For translational longevity research testing multi-pathway intervention hypotheses, the stack design is appropriate — aging is inherently multi-factorial, and single-target interventions in longevity studies consistently show modest effects.

The published lifespan data supports this: Epitalon alone extends maximum lifespan by 12-20% in mice, and NAD+ precursors alone improve healthspan markers but show inconsistent lifespan extension. No combination studies with all three compounds have been published to date, which makes the GLOW stack protocol a genuinely novel research direction with potential for significant findings.